Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What is the recommended dose of aspirin for prevention of colon polyp?
Are you using low dose or full dose aspirin?
Related Questions
Why does NCCN still not recommend using circulating tumor DNA to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?
Are you using Tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroencocrine tumors of GI (non-lung) origins?
Should atezolimab and chemotherapy be considered for stage III dMMR colon cancer with BRAF mutation?
In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
What are your top takeaways from ASCO GI 2026?
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
What adjuvant treatment would you offer a patient with adenocarcinoma of the mid-esophagus cT2N0M0 who underwent upfront esophagectomy, which showed T2N1 disease with negative margins?
How should immunotherapy be incorporated into the treatment strategy for patients with resectable stage III microsatellite instability–high (MSI-H) or mismatch-repair-deficient (dMMR) extrahepatic cholangiocarcinoma?